Among GBMs, two cases were originally diagnosed as anaplastic astrocytoma according to WHO 2016 classification; however, CGPT revealed that they harbored EGFR amplification and TERT promoter mutation, and they were reclassified as GBM based on WHO 2021 classification. The gene discussed is EGFR; the disease is anaplastic astrocytoma.